Zobrazeno 1 - 10 of 75 pro vyhledávání: '"Alfonso de Dios"'
1
Akademický článek
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
Autor: Severine Isabelle Gharbi, Laura A. Pelletier, Alfonso Espada, Jesus Gutiérrez, Sonia Maria Gutiérrez Sanfeliciano, Charles T. Rauch, Maria Patricia Ganado, Carmen Baquero, Elisabet Zapatero, Aiping Zhang, Jordi Benach, Anna-Maria Russell, Leticia Cano, Sandra Gomez, Howard Broughton, Nicholas Pulliam, Carmen Maria Perez, Raquel Torres, Marjoke F. Debets, Alfonso de Dios, Oscar Puig, Mark T. Hilgers, Maria Jose Lallena
Publikováno v: npj Breast Cancer, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract Despite the biological and therapeutic relevance of CDK4/6 for the treatment of HR+, HER2- advanced breast cancer, the detailed mode of action of CDK4/6 inhibitors is not completely understood. Of particular interest, phosphorylation of CDK4
Externí odkaz: https://doaj.org/article/a4901c8cc1f2445081034949720c4383
Zobrazit plný text záznamu
3
Akademický článek
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
Autor: David A. Schaer, Richard P. Beckmann, Jack A. Dempsey, Lysiane Huber, Amelie Forest, Nelusha Amaladas, Yanxia Li, Ying Cindy Wang, Erik R. Rasmussen, Darin Chin, Andrew Capen, Carmine Carpenito, Kirk A. Staschke, Linda A. Chung, Lacey M. Litchfield, Farhana F. Merzoug, Xueqian Gong, Philip W. Iversen, Sean Buchanan, Alfonso de Dios, Ruslan D. Novosiadly, Michael Kalos
Publikováno v: Cell Reports, Vol 22, Iss 11, Pp 2978-2994 (2018)
Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been approved for the treatment of hormone receptor-positive breast cancer. In this study, we use murine syngeneic tumor models and in vitro assays to inves
Externí odkaz: https://doaj.org/article/1595454cd7fc4830988cdc917336d3e6
Zobrazit plný text záznamu
4
Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation
Autor: Raquel, Torres-Guzmán, Maria Patricia, Ganado, Cecilia, Mur, Carlos, Marugan, Carmen, Baquero, Yanzhu, Yang, Yi, Zeng, Huimin, Bian, Jian, Du, Alfonso, de Dios, Oscar, Puig, María José, Lallena
Publikováno v: Oncotarget. 13:864-875
Abemaciclib is an oral, selective cyclin-dependent kinase 46 inhibitor (CDK46i), approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) as monotherapy for endocrine refract
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69dab28f3ef5a47efbcef09588aa74ec
https://doi.org/10.18632/oncotarget.28249
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje